Uncategorized Archives - Page 10 of 134

FridayJul 19, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

The study shows buntanetap is effective in enhancing both motor and cognitive functions, as well as non-motor activities in Parkinson’s Disease patients Following the announcement of these positive results, the company’s stock price surged by 76% The data revealed that while 12% of Parkinson’s Disease patients showed cognitive decline, buntanetap not only halted this decline but also led to improvements Annovis held a webcast to go over the results in more depth, which is available for replay on the company’s website Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative disorders such as Alzheimer’s…

ThursdayJul 18, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Clene plans to submit a briefing book to the U.S. Food and Drug Administration by July 13 as Part of Overall Process to Support Approval for CNM-Au8(R) for Treatment of ALS Type C interaction is aimed at obtaining FDA feedback on the potential pathway for a new drug application for CNM-Au8 as a treatment for ALS via the accelerated approval process The briefing book includes new post-hoc analyses of data from completed clinical trials and addresses comments made by the FDA during a previous meeting in late 2023 Clene (NASDAQ: CLNN) and its wholly owned subsidiary Clene Nanomedicine Inc., a clinical-stage…

WednesdayJul 17, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Annovis has filed a new composition of matter patent with the U.S. Patent and Trademark Office covering novel solid forms of buntanetap, selecting the best crystal, and building upon the provisional patent filed in June 2023 The company’s research focuses on inhibiting the production of multiple neurotoxic proteins that contribute to the progression of neurodegenerative diseases Annovis continues to expand its position in an ongoing fight against neurodegenerative diseases Annovis Bio (NYSE: ANVS), a pioneering biotechnology company, committed to addressing unmet medical needs through innovative research and development efforts, particularly in Alzheimer’s disease, Parkinson’s disease, and other neurodegenerative conditions, is…

MondayJul 08, 2024 12:00 pm

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

For the first time in Medicare’s history, more than half of all eligible people with Medicare are enrolled in private Medicare Advantage plans Enrollment in Medicare Advantage programs is projected to grow from 54% of the eligible population in 2024 to 60% by the end of the decade Astiva Health has developed one of the most diverse networks in Southern California and offers a selection of benefits tailored to the specialized needs of its members According to a recent KFF report, a record number of people enrolled in private Medicare Advantage plans last year (https://ibn.fm/YEpRJ). That trend bodes well for Astiva Health,…

FridayJul 05, 2024 9:00 am

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Clene revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment at the International Rett Syndrome Foundation 2024 Annual Meeting in Westminster, Colorado The only current FDA-approved drug for Rett Syndrome is trofinetide, approved in 2023 CNM-Au8 treatment showed improvements in mitochondrial respiration deficits in Rett patient-derived astrocytes Clene (NASDAQ: CLNN), along with its subsidiary Clene Nanomedicine Inc., a biopharmaceutical company specializing in mitochondrial health to address neurological diseases like amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”), recently revealed new preliminary data on CNM-Au8 for Rett Syndrome treatment. The data was presented by Dr. Karen Ho, Clene’s Vice President…

FridayJun 28, 2024 9:00 am

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

Buntanetap is designed to target neurodegeneration by inhibiting the formation of multiple neurotoxic proteins, including amyloid beta, tau, alpha-synuclein, and TDP43 The study demonstrated significant efficacy and safety for buntanetap in a subgroup of early Alzheimer’s patients in both carriers and non-carriers of Apolipoprotein E4 (APOE4), a recognized genetic factor linked to Alzheimer’s Annovis Bio has been selected to present detailed data from its Alzheimer’s study at the Alzheimer’s Association International Conference(R) 2024 June is Alzheimer’s & Brain Awareness Month, a time dedicated to raising awareness about Alzheimer’s disease and other forms of dementia, as well as the importance of…

WednesdayJun 26, 2024 2:00 pm

BioMedNewsBreaks – Tivic Health(R) Systems (NASDAQ: TIVC) Names New Board Member

Tivic Health(R) Systems (NASDAQ: TIVC), a health tech company that develops and commercializes bioelectronic medicine, today announced the appointment of Christina Valauri to the company’s board of directors, effective July 1, 2024. “Over the past year, as an advisor to our Board and the company, Christina Valauri has demonstrated deep commitment to excellence and the highest standards of ethical governance. This, paired with her insight into capital markets and deep background in research analysis, is a powerful combination to help ensure we make the best decisions for the company, our customers and our shareholders,” TIVC Chair of the Board Sheryle Bolton…

TuesdayJun 25, 2024 9:45 am

Clene Inc. (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial

Clene presented findings on HEALEY ALS at the European Network for the Cure of ALS (ENCALS) meeting held in Stockholm, Sweden The presentation, titled “Long-Term CNM-Au8(R) Treatment Reduces Neurofilament Light Levels and Improves Survival: Results from the HEALEY ALS Platform Trial,” showcased survival follow-up data CNM-Au8 was found to be safe and well-tolerated during the OLE Clene (NASDAQ: CLNN), through its wholly owned subsidiary, Clene Nanomedicine Inc., is a clinical-stage biopharmaceutical company dedicated to enhancing mitochondrial health and safeguarding neuronal function to combat neurodegenerative diseases such as amyotrophic lateral sclerosis (“ALS”) and multiple sclerosis (“MS”). This week, Clene unveiled new…

TuesdayJun 25, 2024 9:00 am

HealthLynked Corp. (HLYK) Digitizes and Streamlines Process of Obtaining Medical Records with New Cutting-Edge Feature Integrated with DocuSign

HealthLynked, a leading provider of healthcare technology solutions, recently launched its new online medical record request form, integrated with DocuSign The new feature allows patients to seamlessly and securely request their medical records from doctors’ offices, hospitals, and laboratories with just a few clicks Through the feature, HealthLynked aims to solve inefficiencies and security issues affecting the flow of health information, helping patients share their medical records with their doctors directly The HIPAA, through the Privacy Rule, aims to allow the flow of health information that can help health care providers to provide high-quality health care and to protect the…

MondayJun 24, 2024 11:15 am

Astiva Health Inc. Dedicated to Serving Growing Number of Older Adults Facing Mental-Health Challenges

Many older adults are at risk of developing mental-health conditions, including depression and anxiety disorders NCOA reports that “fewer than 50% of older adults with mental and/or substance-use disorders receive treatment” Astiva Health is committed to providing strategic, enhanced mental-health services for seniors to help them identify and effectively treat mental-health challenges As baby boomers continue to reach their “golden” years, the number of older adults grappling with mental illness also continues to increase. Astiva Health is committed to providing enhanced mental-health services for its members, as more seniors face mental disorders. “The world’s population is ageing fast,” reports the World Health Organization…

News and publishing service for medical and biotechnology related companies

Contact us: 512.354.7000

Category: Uncategorized

Annovis Bio Inc. (NYSE: ANVS) Announces New Data From Phase III Study of Buntanetap for Early Parkinson’s Disease

Clene Inc. (NASDAQ: CLNN) Announces Plan to Submit Briefing Book to FDA Preceding Type C Interaction

Annovis Bio Inc. (NYSE: ANVS) Files New Composition of Matter Patent for Buntanetap

Astiva Health Inc. Leading the Way as Record Number of People Choose Medicare Advantage Plans

Clene Inc. (NASDAQ: CLNN) Presents Promising Preliminary Data on CNM-Au8(R) for Rett Syndrome Treatment

Annovis Bio Inc. (NYSE: ANVS) Announces Results From Phase II/III Buntanetap Study for the Treatment of Alzheimer’s Disease

BioMedNewsBreaks – Tivic Health(R) Systems (NASDAQ: TIVC) Names New Board Member

Clene Inc. (NASDAQ: CLNN) Reveals Important Findings From HEALEY ALS Platform Trial

HealthLynked Corp. (HLYK) Digitizes and Streamlines Process of Obtaining Medical Records with New Cutting-Edge Feature Integrated with DocuSign

Astiva Health Inc. Dedicated to Serving Growing Number of Older Adults Facing Mental-Health Challenges

Official NewsWire Relationships

BioMedWire Currently Accepts

BioMedWire

Company Search

Site Search